Tax
Federal Tax (Deferred)
Vertex Pharmaceuticals Federal Tax (Deferred) remained flat by 0.0% to -$131.75M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 20.1%, from -$109.68M to -$131.75M. Over 2 years (FY 2023 to FY 2025), Federal Tax (Deferred) shows relatively stable performance with a -3.8% CAGR.
Analysis
StatementIncome Statement
SectionTax
CategoryEfficiency
SignalContext dependent
VolatilityModerate
First reportedQ1 2013
Last reportedQ4 2025
How to read this metric
Significant changes indicate timing differences in depreciation, amortization, or other accounting treatments versus tax code requirements.
Detailed definition
The portion of the income tax provision that is deferred to future periods due to temporary differences between financia...
Peer comparison
Standard tax disclosure for companies with significant capital investments.
Metric ID:
msft_deferred_federal_tax_expenseHistorical Data
3 years
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | -$569.90M | -$438.70M | -$527.00M |
| YoY Change | — | +23.0% | -20.1% |
Range-$569.90M – -$438.70M
CAGR-3.8%
Avg YoY Growth+1.4%
Median YoY Growth+1.4%
Federal Tax (Deferred) at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's federal tax (deferred)?
- Vertex Pharmaceuticals (VRTX) reported federal tax (deferred) of -$131.75M in Q4 2025.
- How has Vertex Pharmaceuticals's federal tax (deferred) changed year-over-year?
- Vertex Pharmaceuticals's federal tax (deferred) decreased by 20.1% year-over-year, from -$109.68M to -$131.75M.
- What is the long-term trend for Vertex Pharmaceuticals's federal tax (deferred)?
- Over 2 years (2023 to 2025), Vertex Pharmaceuticals's federal tax (deferred) has grown at a -3.8% compound annual growth rate (CAGR), from -$569.90M to -$527.00M.
- What does federal tax (deferred) mean?
- Federal taxes that are recognized in the current period but will be paid or realized in future periods.